Interestingly, preclinical studies of the CDK4/6 inhibitor ribociclib in ovarian cancer demonstrated synergistic effects when combined with cisplatin, increasing ovarian cancer cell death (26). This evidence concerns the gene CDK4 and ovarian cancer.